Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28941823 | 1.00 | DGKA (0.52) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL4849680 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL20394156 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL3075652 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL20394158 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL20394142 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL932347 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL20394140 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL21409708 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM | |
| SCHEMBL20394164 | 0.96 | DGKA (0.55) | DGKALMNAMAPTALDH1A1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582678-B2 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | D-PHARM LIMITED (IL) | 2009-09-01 | — | — | US | disclosed |
| EP-1419129-B1 | USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | DPHARM LTD (IL) | 2008-12-03 | — | — | EP | disclosed |
| EP-1419129-A4 | USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | DPHARM LTD (IL) | 2006-05-10 | — | — | EP | disclosed |
| US-20040235949-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | D-PHARM LIMITED (IL) | 2004-11-25 | — | — | US | disclosed |
| EP-1419129-A2 | USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | D-Pharm Limited (IL) | 2004-05-19 | — | — | EP | disclosed |
| US-6518311-B2 | Analgesics | D-PHARM LTD. (IL) | 2003-02-11 | — | — | US | disclosed |
| WO-2003000173-A2 | USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | D-PHARM LIMITED (IL) | 2003-01-03 | — | — | WO | disclosed |
| US-20020042445-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | D-PHARM LTD. (IL) | 2002-04-11 | — | — | US | disclosed |
| US-6251946-B1 | SATURATED OR UNSATURATED BRANCHED FATTY ACID CONTAINING LIPID ESTER OR FATTY ACID AMIDE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING EPILEPSY, MIGRAINES, CHRONIC PAIN AND BIPOLAR DISORDERS | D-PHARM LTD. (IL) | 2001-06-26 | — | — | US | disclosed |
| EP-1009734-A1 | BRANCHED CHAIN FATTY ACIDS, THEIR DERIVATIVES AND USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | D-PHARM, LTD. (IL) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999002485-A1 | BRANCHED CHAIN FATTY ACIDS, THEIR DERIVATIVES AND USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | D-PHARM LTD. (IL) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235949-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | OPRL1, ELOVL5, ELOVL1 | DGKA 911/4885LMNA 2336/4885MAPT 2879/4885 |
| US-20020042445-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | OPRL1, ELOVL5, ELOVL1 | DGKA 911/4885LMNA 2336/4885MAPT 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.